Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.39 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.37 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.37 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.36 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.36 |
| ▸ | LAP3 | P28838 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28458244 | 0.80 | GRIK1 (0.44) | GRIK1GRIK2GPR84CA2CA1 | |
| SCHEMBL28958158 | 0.80 | GRIK1 (0.44) | GRIK1GRIK2GPR84CA2CA1 | |
| SCHEMBL25389975 | 0.80 | GRIK1 (0.44) | GRIK1GRIK2GPR84CA2CA1 | |
| SCHEMBL28021619 | 0.79 | GRIK1 (0.41) | GRIK1GRIK2GPR84CA2CA1 | |
| SCHEMBL28135787 | 0.79 | GRIK1 (0.41) | GRIK1GRIK2GPR84CA2CA1 | |
| SCHEMBL28092773 | 0.79 | GRIK1 (0.41) | GRIK1GRIK2GPR84CA2CA1 | |
| Hydrochloric Acid SCHEMBL11416121 | 0.79 | GRIK1 (0.43) | GRIK1GRIK2GPR84CA2CA1 | |
| SCHEMBL12285998 | 0.78 | CA1 (0.45) | GRIK1GRIK2GPR84CA2CA1 | |
| SCHEMBL19918744 | 0.77 | ACE2 (0.42) | GPR84CA1FFAR1MAPTLCK | |
| SCHEMBL28201654 | 0.77 | CA1 (0.41) | GRIK1GRIK2GPR84CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2458006-B1 | Compounds and methods for modulating expression APOB | IONIS PHARMACEUTICALS INC (US) | 2018-06-20 | — | — | EP | disclosed |
| EP-2363481-B1 | Compounds and methods for modulating gene expression | IONIS PHARMACEUTICALS INC (US) | 2017-04-12 | — | — | EP | disclosed |
| US-9617540-B2 | Compounds and methods for modulating gene expression | IONIS PHARMACEUTICALS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20150344879-A1 | COMPOUNDS AND METHODS FOR MODULATING GENE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-12-03 | — | — | US | disclosed |
| US-9045754-B2 | Short antisense compounds with gapmer configuration | ISIS PHARMACEUTICALS, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-8969316-B2 | Compounds and methods for modulating expression of DGAT2 | ISIS PHARMACEUTICALS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20150057329-A1 | COMPOUNDS AND METHODS FOR MODULATING EXPRESSION APOB | ISIS PHARMACEUTICALS, INC. (US) | 2015-02-26 | — | — | US | disclosed |
| EP-2019692-B1 | COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF GCCR | ISIS PHARMACEUTICALS INC (US) | 2014-06-04 | — | — | EP | disclosed |
| US-8673871-B2 | Compounds and methods for modulating expression ApoB | ISIS PHARMACEUTICALS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8586554-B2 | Compounds and methods for modulating expression of PTP1B | ISIS PHARMACEUTICALS, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20110065775-A1 | COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF SGLT2 | ISIS PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| US-20090326041-A1 | COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF SGLT2 | ISIS PHARMACEUTICALS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090326042-A1 | COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF CRP | ISIS PHARMACEUTICALS, INC (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090318532-A1 | COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF PTP1B | ISIS PHARMACEUTICALS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090306179-A1 | COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF GCGR | ISIS PHARMACEUTICALS INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306005-A1 | COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF PCSK9 | ISIS PHAMACEUTICALS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306180-A1 | COMPOUNDS AND METHODS FOR MODULATING EXPRESSION APOB | ISIS PHARMACEUTICALS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306357-A1 | COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF GCCR | ISIS PHARMACEUTICALS, INC. | 2009-12-10 | — | — | US | disclosed |
| US-20090292006-A1 | COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF DGAT2 | ISIS PHARMACEUTICALS, INC. | 2009-11-26 | — | — | US | disclosed |
| US-20080015162-A1 | COMPOUNDS AND METHODS FOR MODULATING GENE EXPRESSION | IONIS PHARMACEUTICALS, INC. | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015162-A1 | COMPOUNDS AND METHODS FOR MODULATING GENE EXPRESSION | NSUN2, RNMT, METTL16 | GRIK1 2565/4885GRIK2 2417/4885GPR84 3539/4885 |
| US-20090306357-A1 | COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF GCCR | RNMT, NSUN2, HNRNPR | GRIK1 515/4885GRIK2 633/4885GPR84 899/4885 |
| US-20090306180-A1 | COMPOUNDS AND METHODS FOR MODULATING EXPRESSION APOB | APOB, LDLR, HDLBP | GRIK1 3889/4885GRIK2 4028/4885GPR84 2852/4885 |
| US-20110065775-A1 | COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF SGLT2 | SLC5A1, SLC5A2, SLC2A8 | GRIK1 1070/4885GRIK2 873/4885GPR84 633/4885 |
| US-20090326042-A1 | COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF CRP | RBM12, RNGTT, RBM28 | GRIK1 3452/4885GRIK2 3449/4885GPR84 1620/4885 |
| US-20090318532-A1 | COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF PTP1B | PTPRM, PTPA, PTPRCAP | GRIK1 4145/4885GRIK2 4164/4885GPR84 4320/4885 |
| US-20090292006-A1 | COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF DGAT2 | DGAT2, DGAT1, SOAT2 | GRIK1 985/4885GRIK2 806/4885GPR84 1382/4885 |
| US-20090326041-A1 | COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF SGLT2 | SLC5A1, SLC5A2, SLC2A8 | GRIK1 1070/4885GRIK2 873/4885GPR84 633/4885 |
| US-20090306005-A1 | COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF PCSK9 | PCSK9, LDLR, PCSK7 | GRIK1 4023/4885GRIK2 4338/4885GPR84 2440/4885 |
| US-20090306179-A1 | COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF GCGR | RNMT, GCGR, RNGTT | GRIK1 472/4885GRIK2 583/4885GPR84 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.